4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out

Law360, New York (October 16, 2015, 9:26 PM ET) -- The Federal Circuit's refusal to rehear an epic fight between Amgen Inc. and Sandoz Inc. over the Affordable Care Act's biosimilars pathway raises the prospect of U.S. Supreme Court review and leaves critical disputes unresolved, attorneys say.



Friday's refusal left intact a panel decision from July. That decision found that biosimilar makers can skip the pathway's so-called patent dance â€” an exchange of intellectual property information with brand-name rivals. The decision also found that skipping the dance means that biosimilar makers must provide the pathway's 180-day advance-notice...

To view the full article, register now.